A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM).
Ryan J. Sullivan
No relevant relationships to disclose
Nageatte Ibrahim
No relevant relationships to disclose
Donald P. Lawrence
No relevant relationships to disclose
Julie Aldridge
No relevant relationships to disclose
F. Stephen Hodi
No relevant relationships to disclose
Keith Flaherty
No relevant relationships to disclose
Christine Conley
No relevant relationships to disclose
Sarah DeNoble
No relevant relationships to disclose
James Walter Mier
No relevant relationships to disclose
Daniel C. Cho
No relevant relationships to disclose
Michael B. Atkins
No relevant relationships to disclose
David F. McDermott
No relevant relationships to disclose